Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
BMC Clinical Pharmacology|May 16, 2009
Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people, Jane Armitage, Louise Bowman, et al.
Lancet (London, England)|June 20, 2003
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialRory Collins, Jane Armitage, Sarah Parish, et al.
Lancet (London, England)|March 16, 2004
Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditionsRory Collins, Jane Armitage, Sarah Parish, et al.
BMJ (Clinical Research Ed.)|November 14, 2006
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people, Borislava Mihaylova, Andrew Briggs, et al.
Lancet (London, England)|May 25, 2005
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individualsBorislava Mihaylova, Andrew Briggs, Jane Armitage, et al.
International Journal of Epidemiology|April 12, 2003
Stability of plasma analytes after delayed separation of whole blood: implications for epidemiological studiesSarah Clark, Linda D Youngman, Alison Palmer, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|March 9, 2017
Risk prediction for cardiovascular disease using ECG data in the China kadoorie biobankYanting Shen, Yang Yang, Sarah Parish, et al.
Lancet (London, England)|February 1, 2011
C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study, Jonathan Emberson, Derrick Bennett, et al.
Journal of the American College of Cardiology|January 24, 2007
N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study, Jonathan R Emberson, Leong L Ng, et al.
BMJ Open|February 26, 2025
Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetesEmily Sammons, Louise Bowman, William Stevens, et al.
Pageof 9